肝硬化患者血脂异常分析*

doi:10.3969/j.issn.1672-5069.2021.06.023

摘要/Abstract

摘要： 目的分析不同病因和不同Child-Pugh分级的肝硬化患者血脂水平和血脂异常类型。方法 2013年1月～2017年12月我科住院的448例肝硬化患者,其中乙型肝炎194例,丙型肝炎20例,酒精性46例,病毒与酒精性41例,隐源性85例,自身免疫性肝炎33例,NAFLD相关10例和血吸虫病19例。回顾性分析血脂指标,包括总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、载脂蛋白A(APOA)、载脂蛋白B(APOB)。结果在448例肝硬化患者中,221例(49.3%)存在血脂异常,其中低HDL血症207例(93.7%),混合型高脂血症1例(0.5%);186例Child A级患者血TC水平为(3.8±0.9)mmol/L,显著高于183例B级【(3.4±1.3)mmol/L,P<0.01】,或79例C级【(3.1±1.3)mmol/L,P<0.01】;A级TG为(1.1±0.6)mmol/L,显著高于B级【(0.9±0.5)mmol/L,P<0.01】,或C级【(0.9±0.5)mmol/L,P <0.01】;A组HDL为(1.3±0.4)mmol/L,显著高于B级【(1.1±0.4)mmol/L,P <0.01】,或C级【(0.8±0.4)mmol/L,P <0.01】;A级LDL为(2.1±0.6)mmol/L,显著高于B级【(1.8±0.9)mmol/L,P <0.01】,或C级【(1.7±0.8)mmol/L,P <0.01】;A级APOA为(1.1±0.3)mmol/L,显著高于B级【(0.9±0.3)mmol/L,P <0.01】,或C级【(0.8±1.3)mmol/L,P <0.01】;A级APOB为(0.7±0.2)mmol/L,显著高于B级【(0.6±0.3)mmol/L,P <0.01】;随着Child-Pugh分级变差,血脂异常率显著升高,三组分别为32.3%、52.5%和82.3%(P <0.01); NAFLD和丙型肝炎肝硬化患者血脂异常率最高,均为60%,而乙型肝炎肝硬化患者血脂异常率相对较低,为43.8%。结论肝硬化患者血脂异常以低HDL血症最常见,且随着Child-Pugh分级变差而显著升高。NAFLD和丙型肝炎肝硬化患者最容易出现血脂异常,值得关注。

关键词: 肝硬化, 血脂, Child-Pugh分级

Abstract: Objective The aim of this study was to analyze the dyslipidemia in patients with liver cirrhosis (LC). Methods A total of 448 patients with LC were admitted to our hospital between January 2013 and December 2017, and included hepatitis B in 194, hepatitis C in 20, alcohol-induced in 46, hepatitis B or C with alcohol in 41, cryptogenic in 85, autoimmune hepatitis in 33, NAFLD in 10 and schistosomiasis in 19 cases. The blood lipid were analyzed, including total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low density lipoprotein (LDL), apolipoprotein A (APOA) and apolipoprotein B (APOB). Results Out of the 448 patients with LC, 221 cases (49.3%) had dyslipidemia, and the majority of dyslipidemia was low HDL (n=207, 93.7%); the mixed hyperlipidemia was the least (n=1, 0.5%);the blood TC in 186 patients with Child class A was (3.8±0.9) mmol/L, significantly higher than [(3.4±1.3) mmol/L,P<0.01] in 183 patients with class B, or [(3.1±1.3) mmol/L, P <0.01] in 79 patients with class C; the blood TG in class A was (1.1±0.6) mmol/L, significantly higher than [(0.9±0.5) mmol/L, P <0.05] in class B, or [(0.9±0.5) mmol/L, P <0.01] in class C; the HDL level was (1.3±0.4) mmol/L, significantly higher than [(1.1±0.4) mmol/L, P <0.01] in class B, or [(0.8±0.4) mmol/L, P <0.01] in class C; the LDL was (2.1±0.6) mmol/L, significantly higher than [(1.8±0.9) mmol/L, P <0.01] in class B, or [(1.7±0.8) mmol/L, P <0.01] in class C; the APOA was (1.1±0.3) mmol/L, significantly higher than [(0.9±0.3) mmol/L, P <0.01] in class B, or [(0.8±1.3) mmol/L, P <0.01] in class C; the APOB was (0.7±0.2) mmol/L, significantly higher than [(0.6±0.3) mmol/L, P <0.01] in class B; the proportion of dyslipidemia increased significantly with the Child-Pugh classification deteriorated, e.g., the percentages of dyslipidemia was 32.3% in class A, 52.5% in class B, and 82.3% in class C (P <0.01); the dyslipidemia was most common in patients with NAFLD associated (60.0%) and hepatitis C-induced LC (60.0%), and relatively less common in hepatitis B-induced (43.8%). Conclusion Low HDL level is the most common type of dyslipidemia in patients with LC, and as the liver function deteriorates, it becomes common.

Key words: Liver cirrhosis, Blood lipid, Child-Pugh classification

石翠翠, 刘彦君, 章瑞南, 李光明, 范建高. 肝硬化患者血脂异常分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 859-862.

Shi Cuicui, Liu Yanjun, Zhang Ruinan, et al. Dyslipidemia in patients with liver cirrhosis[J]. Journal of Practical Hepatology, 2021, 24(6): 859-862.

参考文献

[1] Bechmann LP, Hannivoort RA, Gerken G, et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol,2012,56(4): 952-964.
[2] Ooi K, Shiraki K, Morishita Y, et al. Clinical significance of abnormal lipoprotein patterns in liver diseases. Int J Mol Med,2005,15(4): 655-660.
[3] Habib A, Mihas AA, Abou SG, et al. High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhosis. Clin Gastroenterol Hepatol,2005,3(3): 286-291.
[4] Mohammad G, Ali R, Abbas H, et al. The relationship between lipid profile and severity of liver damage in cirrhotic patients. Hepat Mon, 2010, 10(4): 285-288.
[5] Makarov VK, Khomeriki SG. Serum lipids as biochemical manifestations of hepatic alcoholic, viral, and mixed viral and alcoholic lesion. Klin Lab Diagn,2007,5(5): 17-19.
[6] Siagris D, Christofidou M, Theocharis GJ, et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat,2006,13(1): 56-61.
[7] Lech C, Lukasz S, Anatol P, et al. The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins. Clin Exp Med,2014,14(4): 417-421.
[8] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版).中国循环杂志,2016,31(10):937-953.
[9] Luisa S, Davide N, Graziella P, et al. Apolipoprotein AI and HDL are reduced in stable cirrhotic patients with adrenal insufficiency: a possible role in glucocorticoid deficiency. Scand J Gastroenterol, 2015, 50(3): 347-354.
[10] Wang B, Tontonoz P. Liver X receptors in lipid signaling and membrane homeostasis. Nature reviews. Endocrinology,2018,14(8): 452-463.
[11] Markus T, Florian R, Vanessa S, et al. HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. J Hepatol,2020,73(1): 113-120.
[12] Pirillo A, Catapano AL, Norata GD. HDL in infectious diseases and sepsis. Handb Exp Pharmacol,2015,224: 483-508.
[13] Kunal S, Bikash S, Subhraprakash P, et al. Lipid profile in alcoholic and nonalcoholic patients of chronic liver disease-a comparative and analytical study in a rural-based tertiary care center. J Assoc Physicians India, 2019, 67(4): 22-24.
[14] Kabbany ZA, Hamza RT, Ibrahim SA, et al. Dyslipidemia and hyperinsulinemia in children and adolescents with chronic liver disease: relation to disease severity. Int J Adolesc Med Health, 2014, 26(2): 195-201.
[15] Graziella P, Luisa S, Simona M, et al. Abnormalities of lipoprotein levels in liver cirrhosis: clinical relevance. Dig Dis Sci, 2018, 63(1): 16-26.
[16] Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol,2017,67(4): 862-873.
[17] 中国研究型医院学会肝病专业委员会,中国医师协会脂肪性肝病专家委员会.脂肪性肝病诊疗规范化的专家建议(2019年修订版).实用肝脏病杂志, 2019, 22(6): 787-792.
[18] Kwarteng JK, Owusu L, Afihene M, et al. Lowered serum triglyceride levels among chronic hepatitis B-infected patients in Ghana. J Sci Technol, 2012, 32(3): 1-10.
[19] Vere CC, Streba CT, Streba L, et al. Lipid serum profile in patients with viral liver cirrhosis. Med Princ Pract,2012,21(6): 566-568.
[20] Carla M, Renata P, Mauricio P, et al. Steatosis in chronic hepatitis C: relationship to the virus and host risk factors. J Gastroenterol Hepatol, 2006, 21(8): 1236-1239.

肝硬化患者血脂异常分析^*

Dyslipidemia in patients with liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吴晓枫, 黄怡, 杨如杏, 邓少东, 张静莹, 官成浓, 王颖. 原发性胆汁性肝硬化患者外周血丝氨酸蛋白酶抑制剂A1基因多态性分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 855-858.
[2]	柳梅, 时永红, 郇娟, 陈茂丽. 失代偿期肝硬化患者并发医院内感染病原菌类别及其耐药特点分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 863-866.
[3]	刘玉玲, 甄增国, 王慧娟, 万秀敏, 郭振凯. 益生菌制剂对肝硬化并发自发性细菌性腹膜炎患者肠道屏障功能的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 867-870.
[4]	邢莉, 杜倩影, 姜艳丽, 韩冬. 分段注射对比剂CT增强扫描提高乙型肝炎肝硬化患者肝静脉显影效果研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 871-874.
[5]	黄力鸥, 吴春荣, 徐丹, 崔宇慧, 唐建国. 无肝素化连续性肾脏替代治疗肝硬化并发肝性脑病患者疗效研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 875-878.
[6]	叶东, 张俊霞, 李洁, 刘颖, 张丹, 郭永泽. 内镜下食管静脉曲张套扎术治疗乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血患者再出血风险观察^*[J]. 实用肝脏病杂志, 2021, 24(6): 879-882.
[7]	韩成美, 韩永峰, 王春华. 乙型肝炎肝硬化患者并发急性肾损伤危险因素分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 883-886.
[8]	王菁, 毕宁, 方亮, 田园. 自体骨髓干细胞经肝动脉肝内移植治疗失代偿期乙型肝炎肝硬化患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(6): 887-890.
[9]	薛魁, 徐银海, 张健. 慢性乙型肝炎和乙型肝炎肝硬化患者血清血小板生成素水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2021, 24(6): 891-894.
[10]	韩利畴, 许望, 韩丹, 邢增珀. 慢性乙型肝炎和乙型肝炎肝硬化患者胃粘膜病变研究[J]. 实用肝脏病杂志, 2021, 24(6): 895-898.
[11]	束青华, 张楠楠, 葛勇胜. 不同HCV基因型感染的慢性丙型肝炎和肝硬化患者对重组人干扰素α-2a治疗应答的影响[J]. 实用肝脏病杂志, 2021, 24(6): 899-902.
[12]	邓江, 石娟娟, 党双锁. 男性慢性肝病患者勃起功能障碍研究进展^*[J]. 实用肝脏病杂志, 2021, 24(6): 934-937.
[13]	赵剑波, 谭卿. 非肝硬化性门静脉高压症研究进展[J]. 实用肝脏病杂志, 2021, 24(5): 613-616.
[14]	谭风雷, 吴亮亮, 邓泽润, 徐峥, 张洁, 张跃新. 夜间加餐对肝硬化患者影响的Meta分析[J]. 实用肝脏病杂志, 2021, 24(5): 625-628.
[15]	李伟, 宋卫东, 谢巴图白音. 采用EVL或TIPS治疗肝硬化并发食管静脉曲张出血患者疗效及其预后分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 629-632.